WALTHAM, Mass., March 2, 2022 /PRNewswire/ -- Ardelyx, Inc.
(Nasdaq: ARDX), a biopharmaceutical company founded with a mission
to discover, develop and commercialize innovative first-in-class
medicines that meet significant unmet medical needs, today
announced that Mike Raab, president
and chief executive officer of Ardelyx, will participate in a
GI/Microbiome panel discussion at the Cowen 42nd Annual Health Care
Conference, which is taking place virtually on Wednesday March 9, 2022, at 10:30 AM Eastern Time.
To access the webcast of the panel presentation please visit the
Events and Presentations page within the Ardelyx website at
https://ir.ardelyx.com/events-and-presentations. A replay of the
panel presentation will be available on the Ardelyx website for 30
days following the event.
About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and
commercialize innovative first-in-class medicines that meet
significant unmet medical needs. Ardelyx received approval for
IBSRELA (tenapanor) with plans to launch in the second quarter of
2022. Ardelyx is developing tenapanor, a novel product candidate to
control serum phosphorus in adult patients with CKD on dialysis,
which has completed three successful Phase 3 trials. Ardelyx is
also advancing RDX013, a potassium secretagogue, for the potential
treatment of elevated serum potassium, or hyperkalemia, a problem
among certain patients with kidney and/or heart disease and has an
early-stage program in metabolic acidosis, a serious electrolyte
disorder in patients with CKD. Ardelyx has established agreements
with Kyowa Kirin in Japan, Fosun
Pharma in China and Knight
Therapeutics in Canada for the
development and commercialization of tenapanor in their respective
territories.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ardelyx-to-participate-at-the-cowen-42nd-annual-health-care-conference-301494555.html
SOURCE Ardelyx